INDEX Stock Overview
InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
InDex Pharmaceuticals Holding AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr0.29 |
52 Week High | kr0.93 |
52 Week Low | kr0.20 |
Beta | -0.23 |
1 Month Change | 4.66% |
3 Month Change | 14.06% |
1 Year Change | -27.63% |
3 Year Change | -83.48% |
5 Year Change | -96.48% |
Change since IPO | -95.83% |
Recent News & Updates
Recent updates
We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate
Jul 11We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Jan 21We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Aug 31Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation
Mar 29InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.
Feb 04How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?
Dec 21Shareholder Returns
INDEX | SE Pharmaceuticals | SE Market | |
---|---|---|---|
7D | 0.7% | -1.0% | -0.6% |
1Y | -27.6% | 74.7% | 13.4% |
Return vs Industry: INDEX underperformed the Swedish Pharmaceuticals industry which returned 81.6% over the past year.
Return vs Market: INDEX underperformed the Swedish Market which returned 17.1% over the past year.
Price Volatility
INDEX volatility | |
---|---|
INDEX Average Weekly Movement | 4.9% |
Pharmaceuticals Industry Average Movement | 6.7% |
Market Average Movement | 6.1% |
10% most volatile stocks in SE Market | 12.9% |
10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: INDEX has not had significant price volatility in the past 3 months.
Volatility Over Time: INDEX's weekly volatility has decreased from 13% to 5% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 7 | Jenny Sundqvist | https://www.indexpharma.com |
InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company’s lead drug candidate is Cobitolimod, which is in phase III clinical development for the treatment of patients with moderate to severe ulcerative colitis. It also develops a portfolio of other DNA based immunomodulatory sequences for the treatment of various immunological diseases.
InDex Pharmaceuticals Holding AB (publ) Fundamentals Summary
INDEX fundamental statistics | |
---|---|
Market cap | kr155.54m |
Earnings (TTM) | -kr95.26m |
Revenue (TTM) | kr97.51m |
1.6x
P/S Ratio-1.6x
P/E RatioIs INDEX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
INDEX income statement (TTM) | |
---|---|
Revenue | kr97.51m |
Cost of Revenue | kr4.16m |
Gross Profit | kr93.35m |
Other Expenses | kr188.61m |
Earnings | -kr95.26m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 08, 2024
Earnings per share (EPS) | -0.18 |
Gross Margin | 95.74% |
Net Profit Margin | -97.70% |
Debt/Equity Ratio | 0% |
How did INDEX perform over the long term?
See historical performance and comparison